Skip to navigation Skip to content

Polycythemia vera (PV) Program in Pharmaceutical Benefits Scheme (PBS) 012-25080641

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised ruxolitinib for patients with polycythemia vera (PV).

PV and listing dates

PV is a rare blood cancer in which the bone marrow produces too many red blood cells. This overproduction thickens the blood, slowing its flow and increasing the risk of serious consequences such as blood clots.

Listing date: ruxolitinib - 1 September 2025.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs